Last Update 01 Jun 26

Fair value Increased 3.54%

UNH: Medicare Reset And Margin Recovery Efforts Will Shape Multi Year Earnings Path

UnitedHealth Group's updated fair value estimate moves from $386.08 to $399.73 as analysts lift price targets in response to expectations of margin recovery in government businesses, steadier Commercial trends, and improved confidence in earnings following Q1 results and guidance.

Analyst Commentary

Street research on UnitedHealth Group has turned more constructive following Q1 results, with several firms lifting price targets and pointing to a clearer earnings path tied to government businesses and Commercial trends.

Bullish Takeaways

Bullish analysts highlight what they see as meaningful earnings potential from margin recovery in Medicare Advantage and other government programs, which feeds directly into higher fair value estimates.
Stronger than expected Q1 medical cost trends and guidance that some analysts describe as having an upward bias are cited as support for higher adjusted EPS outlooks and richer target multiples.
Several research notes point to steadier Commercial business trends and solid Q1 performance across managed care, which, in their view, supports confidence in execution and the ability to sustain earnings quality.
Some analysts refer to UnitedHealth as a top pick within managed care and frame price target increases as reflecting what they see as attractive upside potential tied to a cyclical recovery in margins.

Bearish Takeaways

Even in more constructive reports, some analysts maintain Neutral stances, reflecting caution around the time it may take for margins to return to targeted levels across all businesses.
Commentary points to ongoing cost pressures from specialty drugs, GLP 1 treatments, and behavioral health, which could constrain how quickly margins recover if trends move less favorably.
Some research highlights that, despite raised guidance across managed care, margin pressure remains a consideration, especially as government programs and reimbursement dynamics evolve.
Where analysts use higher target multiples, they also flag that this assumes execution on the margin recovery thesis, leaving less room for error if medical cost trends or policy factors turn less supportive.

What's in the News

UnitedHealth Group reported Q1 2026 adjusted EPS of US$7.23 and revenue of US$111.7b, raised full year adjusted EPS guidance to over US$18.25, and announced a US$2b share repurchase program to be completed by the end of Q2 2026, with shares rising over 8% on the results. Source: UnitedHealth Group Surges on Strong Q1 Earnings Beat and Raised 2026 Outlook
Goldman Sachs added UnitedHealth Group to its U.S. Conviction List with a Buy rating and a US$435 price target after strong Q1 2026 performance and a finalized 2%+ Medicare Advantage payment rate increase for 2027, while several other firms raised their targets as well. Source: Goldman Sachs Adds UnitedHealth to Conviction List Amid Medicare Advantage Recovery and Strong Q1 Performance
UnitedHealthcare plans to remove nearly two thirds of prior authorization requirements for members under age 18 by year end across commercial and Medicaid plans, aiming to reduce paperwork and speed access to pediatric care, including waivers at select pediatric hospitals. Source: UnitedHealthcare to Eliminate Nearly Two Thirds of Pediatric Authorizations by Year End
Massachusetts Attorney General Andrea Joy Campbell sued a UnitedHealthcare unit, alleging inflated illness severity for older Medicaid members and claiming damages of more than US$100m. The company called the complaint meritless. Source: Massachusetts Sues UnitedHealthcare Unit for Alleged Medicaid Fraud
Berkshire Hathaway, led by new CEO Greg Abel, sold its entire roughly 5 million share UnitedHealth Group stake as part of a broader portfolio reshuffle. UnitedHealth Group shares fell over 2% following the announcement. Source: Berkshire Hathaway Sells Entire UnitedHealth Stake Amid CEO Greg Abel's Portfolio Overhaul

Valuation Changes

Fair Value increased from $386.08 to $399.73, implying a modest upward reset in the calculated intrinsic value per share.
The Discount Rate rose from 6.978% to 7.108%, reflecting a slightly higher required return in the updated model.
Revenue Growth remains at 3.04% to 3.04%, with only a very small adjustment in the long term annual growth assumption.
The Net Profit Margin improved from 4.30% to 4.35%, incorporating a small uplift in expected profitability on $ revenue.
The Future P/E increased from 20.53x to 20.99x, indicating a slightly richer valuation multiple in the refreshed outlook.

7 views

Key Takeaways

Strategic investments in technology and value-based programs aim to stabilize revenues and improve operational efficiency and margins.
Adjustments in Medicare strategies and focus on predictive care models may optimize future earnings and healthcare outcomes.
Challenges with Medicare, CMS risk model execution, and external funding pressures adversely impact UnitedHealth Group's financial performance and margins.

Catalysts

About UnitedHealth Group

Operates as a health care company in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The company is addressing unanticipated changes in Medicare membership profiles which impacted 2025 revenue. They are taking measures to ensure complex patients engage in clinical and value-based programs, which should help stabilize and potentially increase future revenue.
UnitedHealth Group is investing in new technology, including improving physician clinical workflows and enhancing digital engagement tools, which could improve operational efficiency and positively impact net margins.
Optum Rx's strong selling season with new wins and high customer retention suggests continued strong revenue performance, supported by efforts to counteract high drug prices and improve access to medicines.
UnitedHealth is planning to adjust Medicare Advantage plan designs and pricing based on observed trends, potentially optimizing future earnings and aligning better with prevailing care costs.
There is an emphasis on expanding value-based care and predictive engagements, such as the HouseCalls program, which may drive better health outcomes and reduce costs, thus improving net margins and overall earnings.

UnitedHealth Group Earnings and Revenue Growth

UnitedHealth Group Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming UnitedHealth Group's revenue will grow by 3.0% annually over the next 3 years.
Analysts assume that profit margins will increase from 2.7% today to 4.4% in 3 years time.
Analysts expect earnings to reach $21.4 billion (and earnings per share of $23.93) by about June 2029, up from $12.0 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $23.9 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 21.0x on those 2029 earnings, down from 28.7x today. This future PE is lower than the current PE for the US Healthcare industry at 23.2x.
Analysts expect the number of shares outstanding to grow by 0.27% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Unexpected increases in care activity and changes in member profiles, particularly in the Medicare businesses, have adversely impacted financial performance, leading to a reduction in projected earnings per share. This negatively influences net margins and earnings.
Insufficient execution in transitioning to the new CMS risk model has resulted in operational complexities and revenue challenges, particularly in the Medicare membership at Optum Health. This impacts revenue and net margins.
Premium increases, especially in the group Medicare Advantage business, have led to higher-than-expected care utilization, straining financial resources and potentially affecting net margins.
Market exits by health plans, driven by CMS risk model changes, have led to new members with lower-than-expected reimbursement levels, affecting Optum Health’s revenue and margins.
External pressures, such as ongoing funding cuts in recent years and concerns over potential future cuts to the Medicare Advantage program, are risks that could further strain net margins and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $399.73 for UnitedHealth Group based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $492.0, and the most bearish reporting a price target of just $287.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $492.0 billion, earnings will come to $21.4 billion, and it would be trading on a PE ratio of 21.0x, assuming you use a discount rate of 7.1%.
Given the current share price of $380.31, the analyst price target of $399.73 is 4.9% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on UnitedHealth Group?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analyst Views Mixed as UnitedHealth Group Price Target Rises Amid Improved Outlook and Ongoing Challenges